Pathophysiology and Management of Acute Respiratory Distress Syndrome in Children.
Pathophysiology and Management of Acute Respiratory Distress Syndrome in Children.
复制标题
DOI：
10.1016/j.pcl.2017.06.004
复制
发表时间：
2017-10
影响因子：
2.6
通讯作者：
Sapru, Anil
中科院分区：
文献类型：
--
作者：
Heidemann, Sabrina M.;Nair, Alison;Bulut, Yonca;Sapru, Anil
急性呼吸窘迫综合征（ARDS）是一种非心源性肺水肿和缺氧的综合征，在儿科重症监护病房中伴随高达30%的死亡。小儿ARDS（PARDS）通过存在缺氧（由氧合指数或PaO 2/FiO 2比值临界值定义）和已知损伤后7天内发生的新胸部浸润来诊断。ARDS中的肺水肿是由在炎症和凝血失调的情况下对肺泡内皮屏障的损伤引起的，导致肺水增加和充气肺组织损失。ARDS的临床特征包括低氧血症和肺顺应性降低、呼吸功增加和气体交换受损。在大多数情况下，死亡伴随着多器官衰竭。虽然已经研究了许多治疗PARDS的方法，但支持性治疗和肺保护性呼吸机支持仍然是治疗的主要手段。
Acute respiratory distress syndrome (ARDS), is a syndrome of non cardiogenic pulmonary edema and hypoxia that accompanies up to 30% of deaths in pediatric intensive care units. Pediatric ARDS (PARDS) is diagnosed by the presence of hypoxia, defined by Oxygenation Index or PaO2/FiO2 ratio cutoffs, and new chest infiltrate occurring within 7 days of a known insult. The pulmonary edema in ARDS is caused by damage to the alveolar endothelial barrier in the setting of dysregulated inflammation and coagulation resulting in increased lung water and loss of aerated lung tissue. Clinical hallmarks of ARDS include hypoxemia and decreased lung compliance, increased work of breathing and impaired gas exchange. Mortality is accompanied by multiple organ failure in most cases. Although many modalities to treat PARDS have been investigated, supportive therapies and lung protective ventilator support remain the mainstay of treatment.
登录
查看更多内容
影响因子：
30.3
作者：
Arezes J;Jung G;Gabayan V;Valore E;Ruchala P;Gulig PA;Ganz T;Nemeth E;Bulut Y
通讯作者：
Bulut Y
影响因子：
158.5
作者：
Amato, MBP;Barbas, CSV;Carvalho, CRR
通讯作者：
Carvalho, CRR
影响因子：
15.9
作者：
Caudrillier, Axelle;Kessenbrock, Kai;Looney, Mark R.
通讯作者：
Looney, Mark R.
影响因子：
10
作者：
Calfee, C. S.;Ware, L. B.;Matthay, M. A.
通讯作者：
Matthay, M. A.
影响因子：
158.5
作者：
Brodie, Daniel;Bacchetta, Matthew
通讯作者：
Bacchetta, Matthew